Skip to content

TAG at 30: Milestones

  • Dorrit Walsh

By Dorrit Walsh and Mark Harrington Since 1992, Treatment Action Group has been advocating for those affected by and struggling with HIV. Since then, we’ve expanded our mission to include tuberculosis (TB) — the leading cause of death by infectious…

Read more

Towards Pandemic Equity: Lessons from 30 Years of Syndemic Activism

  • Dorrit Walsh

By Mike Frick and Mark Harrington The articles in this 30th anniversary issue of TAGline grapple with “pandemic equity,” an increasingly common catchphrase in global health. COVID-19 has shown that “equity,” like its cousins “justice,” “fairness,” and “equality,” is one…

Read more
cover of october 2021 TAGline - title is "delivering on the promise of long-acting formulations, and the image shows many calendar sheets with the names of months to indicate that these are long-acting technologies

TAGline October 2021

  • Dorrit Walsh
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.
Read more

The Challenge of Diagnosing HIV Infection in LA PrEP Users

  • Dorrit Walsh

By Richard Jefferys Impressive results from two efficacy trials of a long-acting form of the integrase inhibitor cabotegravir (CAB LA) have boosted prospects for long-acting HIV pre-exposure prophylaxis (PrEP).1,2 In both cases, CAB LA proved superior to oral Truvada PrEP…

Read more
Back To Top